Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05634499 · ClinicalTrials.gov registry record · Phase 2
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
A Phase 2 study of Endometrial Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 12
- Study locations
NCT05634499 is a Phase 2 study of Endometrial Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 30 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (94% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT05634499, a Phase 2 study of Endometrial Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 12
- Study locations
Study Summary
This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial cancer.
Conditions Studied
Interventions
- DRUG Giredestrant
Study Locations (12)
Quebec
- Jewish General Hospital - Montreal
- McGill University Health Centre - Glen Site - Montreal
Other
- Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice - Gliwice
- Swietokrzyskie Centrum Onkologii - Kielce
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Florida
- Mount Sinai Medical Center - Miami Beach
Minnesota
- Minnesota Oncology Minneapolis - Minneapolis
New Jersey
- Englewood Health/Hematology Oncology Practice of Englewood (HOPE) - Englewood
Pennsylvania
- Western Pennsylvania Hospital - Pittsburgh
Texas
- Texas Oncology, P.A. - Fort Worth - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-27 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05634499
The ClinicalTrials.gov registry entry for NCT05634499 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Giredestrant is the first listed.
NCT05634499 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Quebec, Other, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05634499 about?
NCT05634499 is a clinical study titled "A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer". This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial cancer.
What is the current status of trial NCT05634499?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-06-27. Estimated completion is 2026-06-30.
What conditions does trial NCT05634499 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT05634499?
The interventions under investigation include: Giredestrant (DRUG).
Who is sponsoring clinical trial NCT05634499?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05634499 being conducted?
This trial has 12 study locations across Arkansas, Florida, Minnesota, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.